NASTAD to Provide Testimony about PrEP to House Committee on Oversight and Reform


CONTACT: Kyle Taylor Associate Director, Communications, | 202-897-0029

NASTAD to Provide Testimony about PrEP to House Committee on Oversight and Reform

Tim Horn, Director of Medication Access and Pricing, will provide the testimony at the May 16 hearing

WASHINGTON, DC – NASTAD’s Director of Medication Access and Pricing, Tim Horn, will testify on behalf of NASTAD at the House of Representatives Committee on Oversight and Reform hearing on PrEP on Thursday, May 16. The hearing, titled “HIV Prevention Drug: Billions in Corporate Profits After Millions in Taxpayer Investments,” will take place at 10:00 AM. Aaron Lord of PrEP4All, Dr. Robert Grant of UCSF, Dr. Rochelle Walensky of Harvard Medical School, and Daniel O’Day, CEO of Gilead Sciences, are also expected to testify.

NASTAD’s written testimony, which can be read here, has already been provided to the Committee. In the testimony, Horn focuses on the intersection of the high cost of Truvada as PrEP and the need for effective, comprehensive, affordable – and, importantly, sustainable – public health approaches to HIV prevention in the United States.

“We are failing populations at highest risk for HIV infection, including young Black and Latino gay men, women, and transgender individuals,” said Horn in his testimony. “We are failing them because we have not built the payment and culturally appropriate delivery systems that are best able to reach them. There are many reasons for the low uptake of PrEP in this country, but financing and pricing – the subject of today’s hearing – are undoubtedly among them. In order to end the HIV epidemic, we must build systems that provides access to PrEP for all populations.”

More information about the hearing can be found on the Oversight Committee’s website.


Founded in 1992, NASTAD is a leading non-partisan non-profit association that represents public health officials who administer HIV and hepatitis programs in the U.S. and around the world. Our singular mission is to end the intersecting epidemics of HIV, viral hepatitis, and related conditions. We do this work by strengthening domestic and global governmental public health through advocacy, capacity building, and social justice.